Compare Hormel Foods Corp (HRL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs ResMed Inc. — how do they compare? Hormel Foods Corp trades at $19.23 (market cap $10.69B), while ResMed Inc. trades at $229.4 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 3× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and ResMed Inc. for 51 Days on average.
| HRL | RMD | |
|---|---|---|
Market Cap | $10.69B | $31.89B |
Volume | 10,041,387 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $277.88 |
52-Week Low | $19.42 | $182.82 |
Typical Hold Time | 99 Days | 51 Days |
Enterprise Value | $12.67B | $31.24B |
Dividend Yield | 6.02% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.55, down 1.66% with bearish technical signals. The stock shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, while recent quarterly earnings have consistently beaten expectations. The company's $1.06B Brakebush acquisition aims to expand foodservice presence, though cash flow trends show volatility with 2025 net cash flow negative $71M.
Outlook remains cautious with analyst consensus at Hold (57%) and $24.25 price target suggesting 24% upside. Key risks include declining profit margins, high payout ratios, and integration challenges from recent acquisition. The 60-year dividend streak provides stability but raises sustainability concerns amid shrinking raises.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
